Global Neuroblastoma Chemotherapy Drugs Market 2025 by Manufacturers, Regions, Type and Application, Forecast to 2031
Page: 93
Published Date: 13 Jan 2025
Category: Pharma & Healthcare
PDF Download
Get FREE Sample
Customize Request
-
Description
Table of Contents
Table of Figures
Research Methodology
Companies Mentioned
Related Reports
Product Tags
Table of Contents
Table of Figures
Research Methodology
Companies Mentioned
Related Reports
Product Tags
Description
According to our (Global Info Research) latest study, the global Neuroblastoma Chemotherapy Drugs market size was valued at US$ million in 2024 and is forecast to a readjusted size of USD million by 2031 with a CAGR of %during review period.
Chemotherapy (chemo) is the use of anti-cancer drugs, which are usually given into a vein. The drugs enter the bloodstream and travel throughout the body to reach and destroy cancer cells. This makes chemo useful for treating neuroblastoma, especially if it can"t all be removed with surgery. The most common combination of drugs includes cisplatin (or carboplatin), cyclophosphamide, doxorubicin, vincristine, and etoposide, but others may be used.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Neuroblastoma, a common malignant tumor in children, relies significantly on chemotherapy as part of its comprehensive treatment. Several chemotherapy drugs targeting neuroblastoma are already available in the market, effectively controlling disease progression by interfering with the growth and division of tumor cells. The market size has been gradually expanding due to increasing diagnosis rates and advancements in medical technology, leading to consistent growth in sales of chemotherapy drugs for pediatric neuroblastoma. Looking ahead, with the development of personalized treatments and targeted therapies, neuroblastoma chemotherapy drugs are poised to become more precise in targeting tumor cells, minimizing side effects, and enhancing therapeutic efficacy, thereby offering greater hope for affected children.
This report is a detailed and comprehensive analysis for global Neuroblastoma Chemotherapy Drugs market. Both quantitative and qualitative analyses are presented by manufacturers, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.
Key Features:
Global Neuroblastoma Chemotherapy Drugs market size and forecasts, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2020-2031
Global Neuroblastoma Chemotherapy Drugs market size and forecasts by region and country, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2020-2031
Global Neuroblastoma Chemotherapy Drugs market size and forecasts, by Type and by Application, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2020-2031
Global Neuroblastoma Chemotherapy Drugs market shares of main players, shipments in revenue ($ Million), sales quantity (K Units), and ASP (US$/Unit), 2020-2025
The Primary Objectives in This Report Are:
To determine the size of the total market opportunity of global and key countries
To assess the growth potential for Neuroblastoma Chemotherapy Drugs
To forecast future growth in each product and end-use market
To assess competitive factors affecting the marketplace
This report profiles key players in the global Neuroblastoma Chemotherapy Drugs market based on the following parameters - company overview, sales quantity, revenue, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Baxter Healthcare, Ingenus Pharmaceuticals, ANI Pharmaceuticals, Teva Pharmaceuticals, Qilu Pharmaceutical, Pfizer, Hikma Pharmaceuticals, Fresenius Kabi, Accord Healthcare, Viatris, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
Market Segmentation
Neuroblastoma Chemotherapy Drugs market is split by Type and by Application. For the period 2020-2031, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type
Cyclophosphamide
Cisplatin or Carboplatin
Vincristine
Doxorubicin (Adriamycin)
Etoposide
Other
Market segment by Application
Hospital
Clinic
Other
Major players covered
Baxter Healthcare
Ingenus Pharmaceuticals
ANI Pharmaceuticals
Teva Pharmaceuticals
Qilu Pharmaceutical
Pfizer
Hikma Pharmaceuticals
Fresenius Kabi
Accord Healthcare
Viatris
Market segment by region, regional analysis covers
North America (United States, Canada, and Mexico)
Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
South America (Brazil, Argentina, Colombia, and Rest of South America)
Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)
The content of the study subjects, includes a total of 15 chapters:
Chapter 1, to describe Neuroblastoma Chemotherapy Drugs product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top manufacturers of Neuroblastoma Chemotherapy Drugs, with price, sales quantity, revenue, and global market share of Neuroblastoma Chemotherapy Drugs from 2020 to 2025.
Chapter 3, the Neuroblastoma Chemotherapy Drugs competitive situation, sales quantity, revenue, and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Neuroblastoma Chemotherapy Drugs breakdown data are shown at the regional level, to show the sales quantity, consumption value, and growth by regions, from 2020 to 2031.
Chapter 5 and 6, to segment the sales by Type and by Application, with sales market share and growth rate by Type, by Application, from 2020 to 2031.
Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales quantity, consumption value, and market share for key countries in the world, from 2020 to 2025.and Neuroblastoma Chemotherapy Drugs market forecast, by regions, by Type, and by Application, with sales and revenue, from 2026 to 2031.
Chapter 12, market dynamics, drivers, restraints, trends, and Porters Five Forces analysis.
Chapter 13, the key raw materials and key suppliers, and industry chain of Neuroblastoma Chemotherapy Drugs.
Chapter 14 and 15, to describe Neuroblastoma Chemotherapy Drugs sales channel, distributors, customers, research findings and conclusion.
Table of Contents
1 Market Overview
1.1 Product Overview and Scope
1.2 Market Estimation Caveats and Base Year
1.3 Market Analysis by Type
1.3.1 Overview: Global Neuroblastoma Chemotherapy Drugs Consumption Value by Type: 2020 Versus 2024 Versus 2031
1.3.2 Cyclophosphamide
1.3.3 Cisplatin or Carboplatin
1.3.4 Vincristine
1.3.5 Doxorubicin (Adriamycin)
1.3.6 Etoposide
1.3.7 Other
1.4 Market Analysis by Application
1.4.1 Overview: Global Neuroblastoma Chemotherapy Drugs Consumption Value by Application: 2020 Versus 2024 Versus 2031
1.4.2 Hospital
1.4.3 Clinic
1.4.4 Other
1.5 Global Neuroblastoma Chemotherapy Drugs Market Size & Forecast
1.5.1 Global Neuroblastoma Chemotherapy Drugs Consumption Value (2020 & 2024 & 2031)
1.5.2 Global Neuroblastoma Chemotherapy Drugs Sales Quantity (2020-2031)
1.5.3 Global Neuroblastoma Chemotherapy Drugs Average Price (2020-2031)
2.1 Baxter Healthcare
2.1.1 Baxter Healthcare Details
2.1.2 Baxter Healthcare Major Business
2.1.3 Baxter Healthcare Neuroblastoma Chemotherapy Drugs Product and Services
2.1.4 Baxter Healthcare Neuroblastoma Chemotherapy Drugs Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2020-2025)
2.1.5 Baxter Healthcare Recent Developments/Updates
2.2 Ingenus Pharmaceuticals
2.2.1 Ingenus Pharmaceuticals Details
2.2.2 Ingenus Pharmaceuticals Major Business
2.2.3 Ingenus Pharmaceuticals Neuroblastoma Chemotherapy Drugs Product and Services
2.2.4 Ingenus Pharmaceuticals Neuroblastoma Chemotherapy Drugs Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2020-2025)
2.2.5 Ingenus Pharmaceuticals Recent Developments/Updates
2.3 ANI Pharmaceuticals
2.3.1 ANI Pharmaceuticals Details
2.3.2 ANI Pharmaceuticals Major Business
2.3.3 ANI Pharmaceuticals Neuroblastoma Chemotherapy Drugs Product and Services
2.3.4 ANI Pharmaceuticals Neuroblastoma Chemotherapy Drugs Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2020-2025)
2.3.5 ANI Pharmaceuticals Recent Developments/Updates
2.4 Teva Pharmaceuticals
2.4.1 Teva Pharmaceuticals Details
2.4.2 Teva Pharmaceuticals Major Business
2.4.3 Teva Pharmaceuticals Neuroblastoma Chemotherapy Drugs Product and Services
2.4.4 Teva Pharmaceuticals Neuroblastoma Chemotherapy Drugs Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2020-2025)
2.4.5 Teva Pharmaceuticals Recent Developments/Updates
2.5 Qilu Pharmaceutical
2.5.1 Qilu Pharmaceutical Details
2.5.2 Qilu Pharmaceutical Major Business
2.5.3 Qilu Pharmaceutical Neuroblastoma Chemotherapy Drugs Product and Services
2.5.4 Qilu Pharmaceutical Neuroblastoma Chemotherapy Drugs Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2020-2025)
2.5.5 Qilu Pharmaceutical Recent Developments/Updates
2.6 Pfizer
2.6.1 Pfizer Details
2.6.2 Pfizer Major Business
2.6.3 Pfizer Neuroblastoma Chemotherapy Drugs Product and Services
2.6.4 Pfizer Neuroblastoma Chemotherapy Drugs Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2020-2025)
2.6.5 Pfizer Recent Developments/Updates
2.7 Hikma Pharmaceuticals
2.7.1 Hikma Pharmaceuticals Details
2.7.2 Hikma Pharmaceuticals Major Business
2.7.3 Hikma Pharmaceuticals Neuroblastoma Chemotherapy Drugs Product and Services
2.7.4 Hikma Pharmaceuticals Neuroblastoma Chemotherapy Drugs Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2020-2025)
2.7.5 Hikma Pharmaceuticals Recent Developments/Updates
2.8 Fresenius Kabi
2.8.1 Fresenius Kabi Details
2.8.2 Fresenius Kabi Major Business
2.8.3 Fresenius Kabi Neuroblastoma Chemotherapy Drugs Product and Services
2.8.4 Fresenius Kabi Neuroblastoma Chemotherapy Drugs Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2020-2025)
2.8.5 Fresenius Kabi Recent Developments/Updates
2.9 Accord Healthcare
2.9.1 Accord Healthcare Details
2.9.2 Accord Healthcare Major Business
2.9.3 Accord Healthcare Neuroblastoma Chemotherapy Drugs Product and Services
2.9.4 Accord Healthcare Neuroblastoma Chemotherapy Drugs Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2020-2025)
2.9.5 Accord Healthcare Recent Developments/Updates
2.10 Viatris
2.10.1 Viatris Details
2.10.2 Viatris Major Business
2.10.3 Viatris Neuroblastoma Chemotherapy Drugs Product and Services
2.10.4 Viatris Neuroblastoma Chemotherapy Drugs Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2020-2025)
2.10.5 Viatris Recent Developments/Updates
3.1 Global Neuroblastoma Chemotherapy Drugs Sales Quantity by Manufacturer (2020-2025)
3.2 Global Neuroblastoma Chemotherapy Drugs Revenue by Manufacturer (2020-2025)
3.3 Global Neuroblastoma Chemotherapy Drugs Average Price by Manufacturer (2020-2025)
3.4 Market Share Analysis (2024)
3.4.1 Producer Shipments of Neuroblastoma Chemotherapy Drugs by Manufacturer Revenue ($MM) and Market Share (%): 2024
3.4.2 Top 3 Neuroblastoma Chemotherapy Drugs Manufacturer Market Share in 2024
3.4.3 Top 6 Neuroblastoma Chemotherapy Drugs Manufacturer Market Share in 2024
3.5 Neuroblastoma Chemotherapy Drugs Market: Overall Company Footprint Analysis
3.5.1 Neuroblastoma Chemotherapy Drugs Market: Region Footprint
3.5.2 Neuroblastoma Chemotherapy Drugs Market: Company Product Type Footprint
3.5.3 Neuroblastoma Chemotherapy Drugs Market: Company Product Application Footprint
3.6 New Market Entrants and Barriers to Market Entry
3.7 Mergers, Acquisition, Agreements, and Collaborations
4.1 Global Neuroblastoma Chemotherapy Drugs Market Size by Region
4.1.1 Global Neuroblastoma Chemotherapy Drugs Sales Quantity by Region (2020-2031)
4.1.2 Global Neuroblastoma Chemotherapy Drugs Consumption Value by Region (2020-2031)
4.1.3 Global Neuroblastoma Chemotherapy Drugs Average Price by Region (2020-2031)
4.2 North America Neuroblastoma Chemotherapy Drugs Consumption Value (2020-2031)
4.3 Europe Neuroblastoma Chemotherapy Drugs Consumption Value (2020-2031)
4.4 Asia-Pacific Neuroblastoma Chemotherapy Drugs Consumption Value (2020-2031)
4.5 South America Neuroblastoma Chemotherapy Drugs Consumption Value (2020-2031)
4.6 Middle East & Africa Neuroblastoma Chemotherapy Drugs Consumption Value (2020-2031)
5.1 Global Neuroblastoma Chemotherapy Drugs Sales Quantity by Type (2020-2031)
5.2 Global Neuroblastoma Chemotherapy Drugs Consumption Value by Type (2020-2031)
5.3 Global Neuroblastoma Chemotherapy Drugs Average Price by Type (2020-2031)
6.1 Global Neuroblastoma Chemotherapy Drugs Sales Quantity by Application (2020-2031)
6.2 Global Neuroblastoma Chemotherapy Drugs Consumption Value by Application (2020-2031)
6.3 Global Neuroblastoma Chemotherapy Drugs Average Price by Application (2020-2031)
7.1 North America Neuroblastoma Chemotherapy Drugs Sales Quantity by Type (2020-2031)
7.2 North America Neuroblastoma Chemotherapy Drugs Sales Quantity by Application (2020-2031)
7.3 North America Neuroblastoma Chemotherapy Drugs Market Size by Country
7.3.1 North America Neuroblastoma Chemotherapy Drugs Sales Quantity by Country (2020-2031)
7.3.2 North America Neuroblastoma Chemotherapy Drugs Consumption Value by Country (2020-2031)
7.3.3 United States Market Size and Forecast (2020-2031)
7.3.4 Canada Market Size and Forecast (2020-2031)
7.3.5 Mexico Market Size and Forecast (2020-2031)
8.1 Europe Neuroblastoma Chemotherapy Drugs Sales Quantity by Type (2020-2031)
8.2 Europe Neuroblastoma Chemotherapy Drugs Sales Quantity by Application (2020-2031)
8.3 Europe Neuroblastoma Chemotherapy Drugs Market Size by Country
8.3.1 Europe Neuroblastoma Chemotherapy Drugs Sales Quantity by Country (2020-2031)
8.3.2 Europe Neuroblastoma Chemotherapy Drugs Consumption Value by Country (2020-2031)
8.3.3 Germany Market Size and Forecast (2020-2031)
8.3.4 France Market Size and Forecast (2020-2031)
8.3.5 United Kingdom Market Size and Forecast (2020-2031)
8.3.6 Russia Market Size and Forecast (2020-2031)
8.3.7 Italy Market Size and Forecast (2020-2031)
9.1 Asia-Pacific Neuroblastoma Chemotherapy Drugs Sales Quantity by Type (2020-2031)
9.2 Asia-Pacific Neuroblastoma Chemotherapy Drugs Sales Quantity by Application (2020-2031)
9.3 Asia-Pacific Neuroblastoma Chemotherapy Drugs Market Size by Region
9.3.1 Asia-Pacific Neuroblastoma Chemotherapy Drugs Sales Quantity by Region (2020-2031)
9.3.2 Asia-Pacific Neuroblastoma Chemotherapy Drugs Consumption Value by Region (2020-2031)
9.3.3 China Market Size and Forecast (2020-2031)
9.3.4 Japan Market Size and Forecast (2020-2031)
9.3.5 South Korea Market Size and Forecast (2020-2031)
9.3.6 India Market Size and Forecast (2020-2031)
9.3.7 Southeast Asia Market Size and Forecast (2020-2031)
9.3.8 Australia Market Size and Forecast (2020-2031)
10.1 South America Neuroblastoma Chemotherapy Drugs Sales Quantity by Type (2020-2031)
10.2 South America Neuroblastoma Chemotherapy Drugs Sales Quantity by Application (2020-2031)
10.3 South America Neuroblastoma Chemotherapy Drugs Market Size by Country
10.3.1 South America Neuroblastoma Chemotherapy Drugs Sales Quantity by Country (2020-2031)
10.3.2 South America Neuroblastoma Chemotherapy Drugs Consumption Value by Country (2020-2031)
10.3.3 Brazil Market Size and Forecast (2020-2031)
10.3.4 Argentina Market Size and Forecast (2020-2031)
11.1 Middle East & Africa Neuroblastoma Chemotherapy Drugs Sales Quantity by Type (2020-2031)
11.2 Middle East & Africa Neuroblastoma Chemotherapy Drugs Sales Quantity by Application (2020-2031)
11.3 Middle East & Africa Neuroblastoma Chemotherapy Drugs Market Size by Country
11.3.1 Middle East & Africa Neuroblastoma Chemotherapy Drugs Sales Quantity by Country (2020-2031)
11.3.2 Middle East & Africa Neuroblastoma Chemotherapy Drugs Consumption Value by Country (2020-2031)
11.3.3 Turkey Market Size and Forecast (2020-2031)
11.3.4 Egypt Market Size and Forecast (2020-2031)
11.3.5 Saudi Arabia Market Size and Forecast (2020-2031)
11.3.6 South Africa Market Size and Forecast (2020-2031)
12.1 Neuroblastoma Chemotherapy Drugs Market Drivers
12.2 Neuroblastoma Chemotherapy Drugs Market Restraints
12.3 Neuroblastoma Chemotherapy Drugs Trends Analysis
12.4 Porters Five Forces Analysis
12.4.1 Threat of New Entrants
12.4.2 Bargaining Power of Suppliers
12.4.3 Bargaining Power of Buyers
12.4.4 Threat of Substitutes
12.4.5 Competitive Rivalry
13.1 Raw Material of Neuroblastoma Chemotherapy Drugs and Key Manufacturers
13.2 Manufacturing Costs Percentage of Neuroblastoma Chemotherapy Drugs
13.3 Neuroblastoma Chemotherapy Drugs Production Process
13.4 Industry Value Chain Analysis
14.1 Sales Channel
14.1.1 Direct to End-User
14.1.2 Distributors
14.2 Neuroblastoma Chemotherapy Drugs Typical Distributors
14.3 Neuroblastoma Chemotherapy Drugs Typical Customers
16.1 Methodology
16.2 Research Process and Data Source
16.3 Disclaimer
Table of Figures
List of Tables
Table 1. Global Neuroblastoma Chemotherapy Drugs Consumption Value by Type, (USD Million), 2020 & 2024 & 2031
Table 2. Global Neuroblastoma Chemotherapy Drugs Consumption Value by Application, (USD Million), 2020 & 2024 & 2031
Table 3. Baxter Healthcare Basic Information, Manufacturing Base and Competitors
Table 4. Baxter Healthcare Major Business
Table 5. Baxter Healthcare Neuroblastoma Chemotherapy Drugs Product and Services
Table 6. Baxter Healthcare Neuroblastoma Chemotherapy Drugs Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2020-2025)
Table 7. Baxter Healthcare Recent Developments/Updates
Table 8. Ingenus Pharmaceuticals Basic Information, Manufacturing Base and Competitors
Table 9. Ingenus Pharmaceuticals Major Business
Table 10. Ingenus Pharmaceuticals Neuroblastoma Chemotherapy Drugs Product and Services
Table 11. Ingenus Pharmaceuticals Neuroblastoma Chemotherapy Drugs Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2020-2025)
Table 12. Ingenus Pharmaceuticals Recent Developments/Updates
Table 13. ANI Pharmaceuticals Basic Information, Manufacturing Base and Competitors
Table 14. ANI Pharmaceuticals Major Business
Table 15. ANI Pharmaceuticals Neuroblastoma Chemotherapy Drugs Product and Services
Table 16. ANI Pharmaceuticals Neuroblastoma Chemotherapy Drugs Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2020-2025)
Table 17. ANI Pharmaceuticals Recent Developments/Updates
Table 18. Teva Pharmaceuticals Basic Information, Manufacturing Base and Competitors
Table 19. Teva Pharmaceuticals Major Business
Table 20. Teva Pharmaceuticals Neuroblastoma Chemotherapy Drugs Product and Services
Table 21. Teva Pharmaceuticals Neuroblastoma Chemotherapy Drugs Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2020-2025)
Table 22. Teva Pharmaceuticals Recent Developments/Updates
Table 23. Qilu Pharmaceutical Basic Information, Manufacturing Base and Competitors
Table 24. Qilu Pharmaceutical Major Business
Table 25. Qilu Pharmaceutical Neuroblastoma Chemotherapy Drugs Product and Services
Table 26. Qilu Pharmaceutical Neuroblastoma Chemotherapy Drugs Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2020-2025)
Table 27. Qilu Pharmaceutical Recent Developments/Updates
Table 28. Pfizer Basic Information, Manufacturing Base and Competitors
Table 29. Pfizer Major Business
Table 30. Pfizer Neuroblastoma Chemotherapy Drugs Product and Services
Table 31. Pfizer Neuroblastoma Chemotherapy Drugs Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2020-2025)
Table 32. Pfizer Recent Developments/Updates
Table 33. Hikma Pharmaceuticals Basic Information, Manufacturing Base and Competitors
Table 34. Hikma Pharmaceuticals Major Business
Table 35. Hikma Pharmaceuticals Neuroblastoma Chemotherapy Drugs Product and Services
Table 36. Hikma Pharmaceuticals Neuroblastoma Chemotherapy Drugs Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2020-2025)
Table 37. Hikma Pharmaceuticals Recent Developments/Updates
Table 38. Fresenius Kabi Basic Information, Manufacturing Base and Competitors
Table 39. Fresenius Kabi Major Business
Table 40. Fresenius Kabi Neuroblastoma Chemotherapy Drugs Product and Services
Table 41. Fresenius Kabi Neuroblastoma Chemotherapy Drugs Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2020-2025)
Table 42. Fresenius Kabi Recent Developments/Updates
Table 43. Accord Healthcare Basic Information, Manufacturing Base and Competitors
Table 44. Accord Healthcare Major Business
Table 45. Accord Healthcare Neuroblastoma Chemotherapy Drugs Product and Services
Table 46. Accord Healthcare Neuroblastoma Chemotherapy Drugs Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2020-2025)
Table 47. Accord Healthcare Recent Developments/Updates
Table 48. Viatris Basic Information, Manufacturing Base and Competitors
Table 49. Viatris Major Business
Table 50. Viatris Neuroblastoma Chemotherapy Drugs Product and Services
Table 51. Viatris Neuroblastoma Chemotherapy Drugs Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2020-2025)
Table 52. Viatris Recent Developments/Updates
Table 53. Global Neuroblastoma Chemotherapy Drugs Sales Quantity by Manufacturer (2020-2025) & (K Units)
Table 54. Global Neuroblastoma Chemotherapy Drugs Revenue by Manufacturer (2020-2025) & (USD Million)
Table 55. Global Neuroblastoma Chemotherapy Drugs Average Price by Manufacturer (2020-2025) & (US$/Unit)
Table 56. Market Position of Manufacturers in Neuroblastoma Chemotherapy Drugs, (Tier 1, Tier 2, and Tier 3), Based on Revenue in 2024
Table 57. Head Office and Neuroblastoma Chemotherapy Drugs Production Site of Key Manufacturer
Table 58. Neuroblastoma Chemotherapy Drugs Market: Company Product Type Footprint
Table 59. Neuroblastoma Chemotherapy Drugs Market: Company Product Application Footprint
Table 60. Neuroblastoma Chemotherapy Drugs New Market Entrants and Barriers to Market Entry
Table 61. Neuroblastoma Chemotherapy Drugs Mergers, Acquisition, Agreements, and Collaborations
Table 62. Global Neuroblastoma Chemotherapy Drugs Consumption Value by Region (2020-2024-2031) & (USD Million) & CAGR
Table 63. Global Neuroblastoma Chemotherapy Drugs Sales Quantity by Region (2020-2025) & (K Units)
Table 64. Global Neuroblastoma Chemotherapy Drugs Sales Quantity by Region (2026-2031) & (K Units)
Table 65. Global Neuroblastoma Chemotherapy Drugs Consumption Value by Region (2020-2025) & (USD Million)
Table 66. Global Neuroblastoma Chemotherapy Drugs Consumption Value by Region (2026-2031) & (USD Million)
Table 67. Global Neuroblastoma Chemotherapy Drugs Average Price by Region (2020-2025) & (US$/Unit)
Table 68. Global Neuroblastoma Chemotherapy Drugs Average Price by Region (2026-2031) & (US$/Unit)
Table 69. Global Neuroblastoma Chemotherapy Drugs Sales Quantity by Type (2020-2025) & (K Units)
Table 70. Global Neuroblastoma Chemotherapy Drugs Sales Quantity by Type (2026-2031) & (K Units)
Table 71. Global Neuroblastoma Chemotherapy Drugs Consumption Value by Type (2020-2025) & (USD Million)
Table 72. Global Neuroblastoma Chemotherapy Drugs Consumption Value by Type (2026-2031) & (USD Million)
Table 73. Global Neuroblastoma Chemotherapy Drugs Average Price by Type (2020-2025) & (US$/Unit)
Table 74. Global Neuroblastoma Chemotherapy Drugs Average Price by Type (2026-2031) & (US$/Unit)
Table 75. Global Neuroblastoma Chemotherapy Drugs Sales Quantity by Application (2020-2025) & (K Units)
Table 76. Global Neuroblastoma Chemotherapy Drugs Sales Quantity by Application (2026-2031) & (K Units)
Table 77. Global Neuroblastoma Chemotherapy Drugs Consumption Value by Application (2020-2025) & (USD Million)
Table 78. Global Neuroblastoma Chemotherapy Drugs Consumption Value by Application (2026-2031) & (USD Million)
Table 79. Global Neuroblastoma Chemotherapy Drugs Average Price by Application (2020-2025) & (US$/Unit)
Table 80. Global Neuroblastoma Chemotherapy Drugs Average Price by Application (2026-2031) & (US$/Unit)
Table 81. North America Neuroblastoma Chemotherapy Drugs Sales Quantity by Type (2020-2025) & (K Units)
Table 82. North America Neuroblastoma Chemotherapy Drugs Sales Quantity by Type (2026-2031) & (K Units)
Table 83. North America Neuroblastoma Chemotherapy Drugs Sales Quantity by Application (2020-2025) & (K Units)
Table 84. North America Neuroblastoma Chemotherapy Drugs Sales Quantity by Application (2026-2031) & (K Units)
Table 85. North America Neuroblastoma Chemotherapy Drugs Sales Quantity by Country (2020-2025) & (K Units)
Table 86. North America Neuroblastoma Chemotherapy Drugs Sales Quantity by Country (2026-2031) & (K Units)
Table 87. North America Neuroblastoma Chemotherapy Drugs Consumption Value by Country (2020-2025) & (USD Million)
Table 88. North America Neuroblastoma Chemotherapy Drugs Consumption Value by Country (2026-2031) & (USD Million)
Table 89. Europe Neuroblastoma Chemotherapy Drugs Sales Quantity by Type (2020-2025) & (K Units)
Table 90. Europe Neuroblastoma Chemotherapy Drugs Sales Quantity by Type (2026-2031) & (K Units)
Table 91. Europe Neuroblastoma Chemotherapy Drugs Sales Quantity by Application (2020-2025) & (K Units)
Table 92. Europe Neuroblastoma Chemotherapy Drugs Sales Quantity by Application (2026-2031) & (K Units)
Table 93. Europe Neuroblastoma Chemotherapy Drugs Sales Quantity by Country (2020-2025) & (K Units)
Table 94. Europe Neuroblastoma Chemotherapy Drugs Sales Quantity by Country (2026-2031) & (K Units)
Table 95. Europe Neuroblastoma Chemotherapy Drugs Consumption Value by Country (2020-2025) & (USD Million)
Table 96. Europe Neuroblastoma Chemotherapy Drugs Consumption Value by Country (2026-2031) & (USD Million)
Table 97. Asia-Pacific Neuroblastoma Chemotherapy Drugs Sales Quantity by Type (2020-2025) & (K Units)
Table 98. Asia-Pacific Neuroblastoma Chemotherapy Drugs Sales Quantity by Type (2026-2031) & (K Units)
Table 99. Asia-Pacific Neuroblastoma Chemotherapy Drugs Sales Quantity by Application (2020-2025) & (K Units)
Table 100. Asia-Pacific Neuroblastoma Chemotherapy Drugs Sales Quantity by Application (2026-2031) & (K Units)
Table 101. Asia-Pacific Neuroblastoma Chemotherapy Drugs Sales Quantity by Region (2020-2025) & (K Units)
Table 102. Asia-Pacific Neuroblastoma Chemotherapy Drugs Sales Quantity by Region (2026-2031) & (K Units)
Table 103. Asia-Pacific Neuroblastoma Chemotherapy Drugs Consumption Value by Region (2020-2025) & (USD Million)
Table 104. Asia-Pacific Neuroblastoma Chemotherapy Drugs Consumption Value by Region (2026-2031) & (USD Million)
Table 105. South America Neuroblastoma Chemotherapy Drugs Sales Quantity by Type (2020-2025) & (K Units)
Table 106. South America Neuroblastoma Chemotherapy Drugs Sales Quantity by Type (2026-2031) & (K Units)
Table 107. South America Neuroblastoma Chemotherapy Drugs Sales Quantity by Application (2020-2025) & (K Units)
Table 108. South America Neuroblastoma Chemotherapy Drugs Sales Quantity by Application (2026-2031) & (K Units)
Table 109. South America Neuroblastoma Chemotherapy Drugs Sales Quantity by Country (2020-2025) & (K Units)
Table 110. South America Neuroblastoma Chemotherapy Drugs Sales Quantity by Country (2026-2031) & (K Units)
Table 111. South America Neuroblastoma Chemotherapy Drugs Consumption Value by Country (2020-2025) & (USD Million)
Table 112. South America Neuroblastoma Chemotherapy Drugs Consumption Value by Country (2026-2031) & (USD Million)
Table 113. Middle East & Africa Neuroblastoma Chemotherapy Drugs Sales Quantity by Type (2020-2025) & (K Units)
Table 114. Middle East & Africa Neuroblastoma Chemotherapy Drugs Sales Quantity by Type (2026-2031) & (K Units)
Table 115. Middle East & Africa Neuroblastoma Chemotherapy Drugs Sales Quantity by Application (2020-2025) & (K Units)
Table 116. Middle East & Africa Neuroblastoma Chemotherapy Drugs Sales Quantity by Application (2026-2031) & (K Units)
Table 117. Middle East & Africa Neuroblastoma Chemotherapy Drugs Sales Quantity by Country (2020-2025) & (K Units)
Table 118. Middle East & Africa Neuroblastoma Chemotherapy Drugs Sales Quantity by Country (2026-2031) & (K Units)
Table 119. Middle East & Africa Neuroblastoma Chemotherapy Drugs Consumption Value by Country (2020-2025) & (USD Million)
Table 120. Middle East & Africa Neuroblastoma Chemotherapy Drugs Consumption Value by Country (2026-2031) & (USD Million)
Table 121. Neuroblastoma Chemotherapy Drugs Raw Material
Table 122. Key Manufacturers of Neuroblastoma Chemotherapy Drugs Raw Materials
Table 123. Neuroblastoma Chemotherapy Drugs Typical Distributors
Table 124. Neuroblastoma Chemotherapy Drugs Typical Customers
List of Figures
Figure 1. Neuroblastoma Chemotherapy Drugs Picture
Figure 2. Global Neuroblastoma Chemotherapy Drugs Revenue by Type, (USD Million), 2020 & 2024 & 2031
Figure 3. Global Neuroblastoma Chemotherapy Drugs Revenue Market Share by Type in 2024
Figure 4. Cyclophosphamide Examples
Figure 5. Cisplatin or Carboplatin Examples
Figure 6. Vincristine Examples
Figure 7. Doxorubicin (Adriamycin) Examples
Figure 8. Etoposide Examples
Figure 9. Other Examples
Figure 10. Global Neuroblastoma Chemotherapy Drugs Consumption Value by Application, (USD Million), 2020 & 2024 & 2031
Figure 11. Global Neuroblastoma Chemotherapy Drugs Revenue Market Share by Application in 2024
Figure 12. Hospital Examples
Figure 13. Clinic Examples
Figure 14. Other Examples
Figure 15. Global Neuroblastoma Chemotherapy Drugs Consumption Value, (USD Million): 2020 & 2024 & 2031
Figure 16. Global Neuroblastoma Chemotherapy Drugs Consumption Value and Forecast (2020-2031) & (USD Million)
Figure 17. Global Neuroblastoma Chemotherapy Drugs Sales Quantity (2020-2031) & (K Units)
Figure 18. Global Neuroblastoma Chemotherapy Drugs Price (2020-2031) & (US$/Unit)
Figure 19. Global Neuroblastoma Chemotherapy Drugs Sales Quantity Market Share by Manufacturer in 2024
Figure 20. Global Neuroblastoma Chemotherapy Drugs Revenue Market Share by Manufacturer in 2024
Figure 21. Producer Shipments of Neuroblastoma Chemotherapy Drugs by Manufacturer Sales ($MM) and Market Share (%): 2024
Figure 22. Top 3 Neuroblastoma Chemotherapy Drugs Manufacturer (Revenue) Market Share in 2024
Figure 23. Top 6 Neuroblastoma Chemotherapy Drugs Manufacturer (Revenue) Market Share in 2024
Figure 24. Global Neuroblastoma Chemotherapy Drugs Sales Quantity Market Share by Region (2020-2031)
Figure 25. Global Neuroblastoma Chemotherapy Drugs Consumption Value Market Share by Region (2020-2031)
Figure 26. North America Neuroblastoma Chemotherapy Drugs Consumption Value (2020-2031) & (USD Million)
Figure 27. Europe Neuroblastoma Chemotherapy Drugs Consumption Value (2020-2031) & (USD Million)
Figure 28. Asia-Pacific Neuroblastoma Chemotherapy Drugs Consumption Value (2020-2031) & (USD Million)
Figure 29. South America Neuroblastoma Chemotherapy Drugs Consumption Value (2020-2031) & (USD Million)
Figure 30. Middle East & Africa Neuroblastoma Chemotherapy Drugs Consumption Value (2020-2031) & (USD Million)
Figure 31. Global Neuroblastoma Chemotherapy Drugs Sales Quantity Market Share by Type (2020-2031)
Figure 32. Global Neuroblastoma Chemotherapy Drugs Consumption Value Market Share by Type (2020-2031)
Figure 33. Global Neuroblastoma Chemotherapy Drugs Average Price by Type (2020-2031) & (US$/Unit)
Figure 34. Global Neuroblastoma Chemotherapy Drugs Sales Quantity Market Share by Application (2020-2031)
Figure 35. Global Neuroblastoma Chemotherapy Drugs Revenue Market Share by Application (2020-2031)
Figure 36. Global Neuroblastoma Chemotherapy Drugs Average Price by Application (2020-2031) & (US$/Unit)
Figure 37. North America Neuroblastoma Chemotherapy Drugs Sales Quantity Market Share by Type (2020-2031)
Figure 38. North America Neuroblastoma Chemotherapy Drugs Sales Quantity Market Share by Application (2020-2031)
Figure 39. North America Neuroblastoma Chemotherapy Drugs Sales Quantity Market Share by Country (2020-2031)
Figure 40. North America Neuroblastoma Chemotherapy Drugs Consumption Value Market Share by Country (2020-2031)
Figure 41. United States Neuroblastoma Chemotherapy Drugs Consumption Value (2020-2031) & (USD Million)
Figure 42. Canada Neuroblastoma Chemotherapy Drugs Consumption Value (2020-2031) & (USD Million)
Figure 43. Mexico Neuroblastoma Chemotherapy Drugs Consumption Value (2020-2031) & (USD Million)
Figure 44. Europe Neuroblastoma Chemotherapy Drugs Sales Quantity Market Share by Type (2020-2031)
Figure 45. Europe Neuroblastoma Chemotherapy Drugs Sales Quantity Market Share by Application (2020-2031)
Figure 46. Europe Neuroblastoma Chemotherapy Drugs Sales Quantity Market Share by Country (2020-2031)
Figure 47. Europe Neuroblastoma Chemotherapy Drugs Consumption Value Market Share by Country (2020-2031)
Figure 48. Germany Neuroblastoma Chemotherapy Drugs Consumption Value (2020-2031) & (USD Million)
Figure 49. France Neuroblastoma Chemotherapy Drugs Consumption Value (2020-2031) & (USD Million)
Figure 50. United Kingdom Neuroblastoma Chemotherapy Drugs Consumption Value (2020-2031) & (USD Million)
Figure 51. Russia Neuroblastoma Chemotherapy Drugs Consumption Value (2020-2031) & (USD Million)
Figure 52. Italy Neuroblastoma Chemotherapy Drugs Consumption Value (2020-2031) & (USD Million)
Figure 53. Asia-Pacific Neuroblastoma Chemotherapy Drugs Sales Quantity Market Share by Type (2020-2031)
Figure 54. Asia-Pacific Neuroblastoma Chemotherapy Drugs Sales Quantity Market Share by Application (2020-2031)
Figure 55. Asia-Pacific Neuroblastoma Chemotherapy Drugs Sales Quantity Market Share by Region (2020-2031)
Figure 56. Asia-Pacific Neuroblastoma Chemotherapy Drugs Consumption Value Market Share by Region (2020-2031)
Figure 57. China Neuroblastoma Chemotherapy Drugs Consumption Value (2020-2031) & (USD Million)
Figure 58. Japan Neuroblastoma Chemotherapy Drugs Consumption Value (2020-2031) & (USD Million)
Figure 59. South Korea Neuroblastoma Chemotherapy Drugs Consumption Value (2020-2031) & (USD Million)
Figure 60. India Neuroblastoma Chemotherapy Drugs Consumption Value (2020-2031) & (USD Million)
Figure 61. Southeast Asia Neuroblastoma Chemotherapy Drugs Consumption Value (2020-2031) & (USD Million)
Figure 62. Australia Neuroblastoma Chemotherapy Drugs Consumption Value (2020-2031) & (USD Million)
Figure 63. South America Neuroblastoma Chemotherapy Drugs Sales Quantity Market Share by Type (2020-2031)
Figure 64. South America Neuroblastoma Chemotherapy Drugs Sales Quantity Market Share by Application (2020-2031)
Figure 65. South America Neuroblastoma Chemotherapy Drugs Sales Quantity Market Share by Country (2020-2031)
Figure 66. South America Neuroblastoma Chemotherapy Drugs Consumption Value Market Share by Country (2020-2031)
Figure 67. Brazil Neuroblastoma Chemotherapy Drugs Consumption Value (2020-2031) & (USD Million)
Figure 68. Argentina Neuroblastoma Chemotherapy Drugs Consumption Value (2020-2031) & (USD Million)
Figure 69. Middle East & Africa Neuroblastoma Chemotherapy Drugs Sales Quantity Market Share by Type (2020-2031)
Figure 70. Middle East & Africa Neuroblastoma Chemotherapy Drugs Sales Quantity Market Share by Application (2020-2031)
Figure 71. Middle East & Africa Neuroblastoma Chemotherapy Drugs Sales Quantity Market Share by Country (2020-2031)
Figure 72. Middle East & Africa Neuroblastoma Chemotherapy Drugs Consumption Value Market Share by Country (2020-2031)
Figure 73. Turkey Neuroblastoma Chemotherapy Drugs Consumption Value (2020-2031) & (USD Million)
Figure 74. Egypt Neuroblastoma Chemotherapy Drugs Consumption Value (2020-2031) & (USD Million)
Figure 75. Saudi Arabia Neuroblastoma Chemotherapy Drugs Consumption Value (2020-2031) & (USD Million)
Figure 76. South Africa Neuroblastoma Chemotherapy Drugs Consumption Value (2020-2031) & (USD Million)
Figure 77. Neuroblastoma Chemotherapy Drugs Market Drivers
Figure 78. Neuroblastoma Chemotherapy Drugs Market Restraints
Figure 79. Neuroblastoma Chemotherapy Drugs Market Trends
Figure 80. Porters Five Forces Analysis
Figure 81. Manufacturing Cost Structure Analysis of Neuroblastoma Chemotherapy Drugs in 2024
Figure 82. Manufacturing Process Analysis of Neuroblastoma Chemotherapy Drugs
Figure 83. Neuroblastoma Chemotherapy Drugs Industrial Chain
Figure 84. Sales Channel: Direct to End-User vs Distributors
Figure 85. Direct Channel Pros & Cons
Figure 86. Indirect Channel Pros & Cons
Figure 87. Methodology
Figure 88. Research Process and Data Source
Research Methodology
Client Requirements
Review and analyze client requirements
Discussion of all the project requirements and queries
Flexibility Check
Project Feasibility Analysis
Finalizing tentative research programme
Structuring project proposal with scope, timeline, and costs
Analyzing Market Dynamics
Determination of key drivers, restraints, challenge, and opportunity
Identifies market needs and trends
Market Size Estimation & Forecast
Estimation of historical data based on secondary and primary data
Anticipating market recast by assigning weightage to market forces (drivers, restraints, opportunities)
Freezing historical and forecast market size estimations based on evolution, trends, outlook, and strategies
Consideration of geography, region-specific product/service demand for region segments
Consideration of product utilization rates, product demand outlook for segments by application or end-user.
Data Source
Secondary Source
Data collections from annual reports, presentations,associations, journals, analyst reports,
paid database, press releases, blogs, newsletters,and GIR repositories.
Primary Source
Research discussion with manufacturers, distributors, suppliers, end user, industry experts
to verify insights.
Validation
and
triangulation of
secondary and primary source.
Collection of data
Cumulating and collating the essential qualitative and quantitative data
Generation of report in client requested format by research analysts
Reviews by expert analysts
Final quality check
Clarifying queries
Receiving feedback
Ensuring satisfaction
01 Identification of data
This step involves identification of several primary and secondary data research sources, including Global Info Research's internal data sources. The primary sources consist of in-depth discussions and interviews with policy makers, industry experts, and data evaluators, whereas secondary sources include a thorough study of market journals, press releases, annual reports, and government and non-government agencies websites.
-
02 Evaluation of Market Dynamic
This phase includes a detailed evaluation of several factors that are likely to affect the market dynamics. It involves a comprehensive assessment of major market pain points, drivers, and trends. It also comprises a detailed study of research plans and methodology.
-
03 Collection of Data
This process consists of gathering data, accessing proprietary databases, and reaching out to key industry participants that operate in the market across the value chain. It also involves studying several patterns in the historical data and comparing it with the current scenario.
-
04 Collaboration of Data
This stage involves the validation of data and arrival at actual statistics, and evolution of the market over the years. It entails the study and analyzes various segments and verticals of the market. An impact analysis is also performed to observe which factors will affect the market in the next few years.
05 Verification and Analysis
This is the final stage, which involves both quantity and quality checks. Although the process of data verification is an integral part of the research process, all data points and statistics and figures are re-checked to uphold their authenticity and validity.
Companies Mentioned
Baxter Healthcare Ingenus Pharmaceuticals ANI Pharmaceuticals Teva Pharmaceuticals Qilu Pharmaceutical Pfizer Hikma Pharmaceuticals Fresenius Kabi Accord Healthcare Viatris
Related Reports
20 Feb 2023
Pharma & Healthcare
Purchase Options
Add To Cart
Buy Now
Popular Product Keywords
- We Provide Professional, Accurate Market Analysis to Help You Stay Ahead of Your Competition.Speak to our analyst >>
Our Clients
What We Can Provide?
With better results and higher quality products,Our professional reports can achieve four things:
Insight into the industry market information
Analyze market development needs
Prospects for future development
Develop industry investment strategy
- Digging deeper into global industry information and providing market strategies.Contact Us >>
